A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis

Study Identifier
GMA-LAS-011-001
CT.gov Identifier
NCT01470118
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Conjunctivitis
    • Study Drug
  • alcaftadine 0.25% ophthalmic solution
  • olopatadine 0.2% ophthalmic solution
  • dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
    • Phase
    Phase 4
    Sex
    Female & Male
    Age
    10+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * History of eye allergies within the past 24 months * Willing to not wear contact lenses at least 72 hours prior to the study start and during the study period
    Exclusion Criteria:
    * Current eye infection * Eye surgery within 3 months or vision correction surgery within 6 months * Any planned surgery during the study or 30 days after the study

    Protocol Summary

    This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis.

    Study Locations

    Location
    Status
    Location
    Philadelphia, Pennsylvania, United States
    Status
    Not applicable